Guo Ke-Tai, Yan Xin-Rui, Huang Guo-Jin, Xu Chun-Xiao, Chai Ying-Shuang, Zhang Zhi-Qing
State Key Laboratory of Molecular Virology and Genetic Engineering, Institute of Virology, China Center for Disease Control and Prevention, Beijing 100052, China.
Sheng Wu Gong Cheng Xue Bao. 2003 Nov;19(6):730-3.
Human tumor necrosis factor alpha (hTNF-alpha) is one of the most important inflammatory cytokines that acts as a mediator in inflammatory and immune response and plays a key role in host defense against infection. The over expression of hTNF-alpha is associated with serious consequences, such as shock, hypotension, thrombus, septicemia and even death. It has been implicated in many autoimmune and inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, chronic heart failure and septic shock. Inhibiting the bio-activity of hTNF-alpha is one of the strategy for the treatment of these diseases. Compared with traditional recombinant protein drugs, small molecule drugs have many advantages, such as high affinity, low immunogenecity and low cost. Systematic evolution of ligands by exponential enrichment (SELEX) is a powerful method for the selection of oligonucleotides that bind with high affinity and specificity to target proteins. Such oligonucleotides are called aptamers, and are potential therapeutics for blocking the activity of pathologically relevant proteins. To obtain oligonucleotide aptamers specifically binding to TNF, a 40nt random DNA combinatorial library flanked by 31nt fixed sequences was chemically synthesized. The random library was amplified with PCR and subjected to selection by SELEX protocol against hTNFalpha. After incubation of the library with hTNFalpha, the mixture was blotted onto Immobilon-NC transfer membrane. The no-specific binding was washed away and the hTNFa binding aptamers were eluted and detached from the target protein. The eluted oligo nucleotides were amplified with PCR and served as the DNA library for the next round selection. After 12 rounds of such selection, the selected aptamers were cloned to pGEM-T vector. Positive clones were identified by restriction enzyme digestion and DNA sequencing. Oligo DNA were synthesized according to the sequence data and tested for their activities. Binding activity of the aptamers to hTNFalpha were detected by ELISA and dot blot with biotin-streptavidin-horseradish peroxidase system. Mouse L929 cells were used to test the anti-hTNFa activity of the DNA aptamers. The aptamers were incubated with hTNFalpha and added to the L929 cells. The results were read under microscope and with MTT staining. It was shown that these DNA aptamers bound to hTNFalpha with high affinity, and can inhibit the cytotoxicity of hTNFalpha on cell culture. The affinity of these aptamers are different and may related to their structure. These ssDNA aptamers are potential for the treatment and diagnosis of hTNFalpha related diseases.
人肿瘤坏死因子α(hTNF-α)是最重要的炎症细胞因子之一,在炎症和免疫反应中起介质作用,在宿主抗感染防御中发挥关键作用。hTNF-α的过度表达会带来严重后果,如休克、低血压、血栓、败血症甚至死亡。它与许多自身免疫性和炎症性疾病有关,如类风湿性关节炎、克罗恩病、慢性心力衰竭和败血性休克。抑制hTNF-α的生物活性是治疗这些疾病的策略之一。与传统重组蛋白药物相比,小分子药物具有许多优点,如高亲和力、低免疫原性和低成本。指数富集配体系统进化技术(SELEX)是一种强大的方法,用于选择与靶蛋白具有高亲和力和特异性结合的寡核苷酸。这种寡核苷酸被称为适配体,是阻断病理相关蛋白活性的潜在治疗剂。为了获得特异性结合TNF的寡核苷酸适配体,化学合成了一个两侧带有31nt固定序列的40nt随机DNA组合文库。通过PCR扩增随机文库,并根据SELEX方案针对hTNFα进行筛选。将文库与hTNFα孵育后,将混合物点样到Immobilon-NC转移膜上。洗去非特异性结合物,洗脱并使与靶蛋白结合的hTNFα适配体脱离。洗脱的寡核苷酸通过PCR扩增,并用作下一轮筛选的DNA文库。经过12轮这样的筛选后,将所选的适配体克隆到pGEM-T载体中。通过限制性内切酶消化和DNA测序鉴定阳性克隆。根据序列数据合成寡核苷酸DNA并测试其活性。通过ELISA和生物素-链霉亲和素-辣根过氧化物酶系统的点杂交检测适配体与hTNFα的结合活性。使用小鼠L929细胞测试DNA适配体的抗hTNFα活性。将适配体与hTNFα孵育后加入到L929细胞中。在显微镜下和通过MTT染色读取结果。结果表明,这些DNA适配体与hTNFα具有高亲和力,并且可以抑制hTNFα对细胞培养的细胞毒性。这些适配体的亲和力不同,可能与其结构有关。这些单链DNA适配体在治疗和诊断hTNFα相关疾病方面具有潜力。